Navigation Links
Aton Pharma Appoints Dr. Wayne Mulcahy to Vice President, Clinical Operations
Date:2/16/2010

LAWRENCEVILLE, N.J., Feb. 16 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, announced today that Wayne S. Mulcahy, Ph.D., has joined the company as Vice President, Clinical Operations. A wholly owned subsidiary of Princeton Pharma Holdings LLC, Aton is focused on the development and commercialization of unique products in ophthalmology and orphan diseases.

The company's comprehensive portfolio of well-established specialty pharmaceuticals targets cardiovascular (Mephyton®, Edecrin®, Sodium Edecrin®), metabolic (Cuprimine®, Syprine®, Demser®) and ophthalmic (Lacrisert® and the Timoptic® product line) diseases.

With more than 30 years of experience in clinical operations, Dr. Mulcahy has been responsible for the development and management of clinical programs across a range of therapeutic classes, including cardiovascular and CNS disorders, experience which is highly relevant to the clinical programs he will lead for Aton.

"Dr. Mulcahy's extensive scientific, clinical and regulatory background will provide exemplary leadership for Aton's burgeoning pipeline of development programs," said Michael G. Wells, Chief Executive Officer of Aton Pharma. "His technical acumen and strong track record of NDA submissions will help Aton fulfill its mission of bringing innovative and medically necessary medications to patients in need around the world."

Prior to joining Aton, Dr. Mulcahy served as Vice President of Research and Development at Alita Pharmaceuticals, as Vice President of Clinical Operations at the Duramed Research subsidiary of Barr Pharmaceuticals and as Senior Director of Scientific and Regulatory Affairs at Teva Pharmaceuticals North America. He began his pharmaceutical career at Merck Research Laboratories where he was awarded a Doctoral Study Fellowship. Dr. Mulcahy earned his Ph.D. in pharmacology from Temple University School of Medicine, an M.S. from Drexel University and his B.A. from Arcadia University.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global, diversified specialty pharmaceutical company providing essential treatments for under-treated diseases. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of products, with sales in over 30 countries, focuses on ophthalmic diseases and orphan conditions. For more information, see www.atonrx.com.

SOURCE Aton Pharma, Inc.

RELATED LINKS
http://www.atonrx.com

'/>"/>

SOURCE Aton Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VPCI Pioneers Virtual GMP Consulting for FDA Pharmaceutical Manufacturers
2. International Merchant Advisors, Inc. Signs LOI to Invest in Pharmaceutical Chain
3. Albemarle(R) Announces Custom Manufacturing Alliance with PharmaCore(R)
4. Bioniche Pharma Acquires Seven New Products From GeneraMedix Inc.
5. International Merchant Advisors, Inc. Offers to Invest in Pharmaceutical Chain
6. Endo Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on February 22, 2010
7. Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results
8. PARI Pharma Enrolls First Patient in Phase 2b Study of L-CsA
9. Creative Alliances with Nontraditional Players Increasingly Essential for Survival in Pharmaceutical Industry, New Ernst & Young Report Finds
10. Berkery Noyes Releases 2009 Pharma and Healthcare Information Merger & Acquisition Trends
11. Expanded London Genetics Web Site Emphasises Importance of Pharmacogenetics in Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... PARIS , May 25, 2016 ... system disorders, announces that an oral presentation entitled "High doses ... the MS-SPI trial" will be given by Professor Ayman ... the 2nd Congress of the European Academy of Neurology (EAN) ... "MS and related disorders 3" will take place on Sunday, ...
(Date:5/25/2016)... May 25, 2016 Inivata, ... precision of circulating tumour DNA (ctDNA) analysis to ... appointment of Professor Clive Morris as ... across the clinical development programme, scientific collaborations, and ... deliver significant improvements in clinical outcomes for patients. ...
(Date:5/25/2016)... , May 25, 2016 ... 2016"market research report that provides an overview on ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ... reviews key players involved in the therapeutic development ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... For more than fifty years, we've suffered whiplash as each new ... to conform to the latest nutritional advice – advice that was supposed to keep us ... 2 in 3 American adults are considered to be overweight and more than 1 in ...
(Date:5/25/2016)... FLA (PRWEB) , ... May 25, 2016 , ... ... technology to help turn back the hands of time of female aging. The ... and childbirth. Women with symptoms such as leakage, laxity, itchiness and pain have ...
(Date:5/25/2016)... Aliso Viejo, CA (PRWEB) , ... May 25, 2016 , ... ... will amplify the quality of your footage," said Christina Austin - CEO of Pixel ... Film Studios, editors can quickly and easily add stylish color grades to their footage. ...
(Date:5/25/2016)... ... May 25, 2016 , ... BeniComp Insurance Company, ... spike in their clients' employee participation for their wellness initiatives. BeniComp clients ... a high-deductible health plan with outcome-based deductible incentives. As a result, BeniComp clients ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... Researchers from ... Annual COVD Meeting for their work on visual evoked potential and human attention. The ... studies that used the Diopsys® NOVA™ ERG and VEP Vision Testing System ...
Breaking Medicine News(10 mins):